OBJECTIVES: The aim of the study was to compare the cost per responder (CPR) of bimekizumab, a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A, against other approved IL-17A, IL-12/23 and IL-23 inhibitors for the treatment of psoriatic arthritis (PsA) in the UK.

METHODS: A 16 to 24-week CPR model was developed based on a published network meta-analysis. The CPR tool included the Psoriatic Arthritis Response Criteria (PsARC), the American College of Rheumatology (ACR) score, and the Psoriasis Area and Severity Index (PASI) score outcome measures in patients with PsA. PsARC, ACR50, PASI100, and PASI90 response rates were used in the model to assess treatment outcomes in PsA. The cost of drugs was based on the 2023 NHS list price available in the British National Formulary and dose recommendations. The CPR was estimated by multiplying the number of doses in the first 16 weeks of treatment by the NHS list price divided by the response rate. Biologics included in the analysis were bimekizumab, secukinumab, ixekizumab, guselkumab, ustekinumab, and risankizumab.

RESULTS: Bimekizumab demonstrated the lowest cost per PsARC, ACR50, PASI100, and PASI90-response in both bio-naïve (£7,830, £14,542, £12,995, and £9,851 respectively) and bio-experienced patients (£7,185, £13,277, £10,530, and £8,725 respectively). Ustekinumab had the highest cost per PsARC response in the bio-naïve (£10,917) and bio-experienced (£11,067) population. Risankizumab had the highest cost per ACR50 response of £39,913 in both bio-naïve and bio-experienced patients. Secukinumab demonstrated the highest cost per PASI100 (£32,033) in the bio-naïve population whilst ixekizumab had the highest cost per PASI100 (£39,706) in the bio-experienced population.

CONCLUSIONS: The results demonstrate that treatment with bimekizumab for patients with PsA at week 16-24 is associated with the lowest cost per PsARC, ACR50, PASI100, and PASI90 response versus approved IL-inhibitors in both bio-naïve and bio-experienced patients in the UK.